Matthias Schwenkglenks

ORCID: 0000-0001-7217-1173
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Health Systems, Economic Evaluations, Quality of Life
  • Neutropenia and Cancer Infections
  • Atrial Fibrillation Management and Outcomes
  • Pharmaceutical Practices and Patient Outcomes
  • Economic and Financial Impacts of Cancer
  • Cancer Treatment and Pharmacology
  • Meta-analysis and systematic reviews
  • Blood disorders and treatments
  • Chronic Disease Management Strategies
  • Colorectal Cancer Treatments and Studies
  • Influenza Virus Research Studies
  • Breast Cancer Treatment Studies
  • Medication Adherence and Compliance
  • Healthcare Policy and Management
  • Pharmaceutical Economics and Policy
  • Lung Cancer Treatments and Mutations
  • Lymphoma Diagnosis and Treatment
  • Chronic Lymphocytic Leukemia Research
  • Ethics in Clinical Research
  • Iron Metabolism and Disorders
  • Cardiac Arrhythmias and Treatments
  • Heart Failure Treatment and Management
  • Healthcare cost, quality, practices
  • Venous Thromboembolism Diagnosis and Management
  • Advanced Breast Cancer Therapies

University of Basel
2016-2025

University of Zurich
2016-2025

University Hospital of Basel
2007-2022

Hospital Base
2022

Swiss Tropical and Public Health Institute
2022

Prevention Institute
2021-2022

University Hospital of Zurich
2000-2022

Careers Europe
2021

Kantonsspital Graubünden
2021

National Cancer Registration Service
2021

<h3>Importance</h3> The discontinuation of randomized clinical trials (RCTs) raises ethical concerns and often wastes scarce research resources. epidemiology discontinued RCTs, however, remains unclear. <h3>Objectives</h3> To determine the prevalence, characteristics, publication history RCTs to investigate factors associated with RCT due poor recruitment nonpublication. <h3>Design Setting</h3> Retrospective cohort based on archived protocols approved by 6 ethics committees in Switzerland,...

10.1001/jama.2014.1361 article EN JAMA 2014-03-11
David Conen Nicolas Rodondi A. Müller Jürg H. Beer Peter Ammann and 95 more Giorgio Moschovitis Angelo Auricchio Daniel Hayoz Richard Kobza Dipen Shah Jan Novák Jürg Schläpfer Marcello Di Valentino Stefanie Aeschbacher Steffen Blum Pascal Meyre Christian Sticherling Leo H. Bonati Georg Ehret Elisavet Moutzouri Urs Fischer Andreas U. Monsch Christoph Stippich Jens Wuerfel Tim Sinnecker Michael Coslovsky Matthias Schwenkglenks Michael Kühne Stefan Osswald Sebastian Berger Raffaele Bernasconi L. Fröhlich Tobias Göldi Rebecca Gugganig Thomas Kofler Philipp Krisai Michel Mongiat Christiane Pudenz Francisco Javier Ruperti‐Repilado Aleksandra Schweizer Anne Springer Samuel Stempfel Thomas D. Szucs Jan van der Stouwe Gian Voellmin Leon Zwimpfer Drahomir Aujesky Juerg Fuhrer Laurent Roten Simon Jung Heinrich P. Mattle Luise Adam Carole E. Aubert Martin Feller Claudio Schneider Axel Loewe Tanja Flückiger Cindy Groen Nathalie Schwab Christopher Beynon Roger Dillier Franz R. Eberli Simone Fontana C Franzini Isabel Juchli Claudia Liedtke Jacqueline Nadler Thayze Obst Xiaoye Schneider Katrin Studerus Dominik Weishaupt Silke Küest Karin Scheuch Denise Hischier Nicole R. Bonetti Corina Bello Henriette Isberg Alexandra Grau Jonas Villinger Mary-Monica Papaux Philipp Baumgartner Mark G. Filipovic Marcel Frick Adriana Anesini Cristina Camporini Giulio Conte Maria Luce Caputo François Regoli Tiziano Moccetti Roman Brenner David Altmann Manuela Forrer Michaela Gemperle Mathieu Firmann Sandrine Foucras Benjamin Berte Andrea Kaeppeli Brigitta Mehmann Markus Pfeiffer Ian Russi

10.1016/j.jacc.2018.12.039 article EN Journal of the American College of Cardiology 2019-03-01

Abstract Objective To examine the effect of optimising drug treatment on related hospital admissions in older adults with multimorbidity and polypharmacy admitted to hospital. Design Cluster randomised controlled trial. Setting 110 clusters inpatient wards within university based hospitals four European countries (Switzerland, Netherlands, Belgium, Republic Ireland) defined by attending doctors. Participants 2008 (≥70 years) (≥3 chronic conditions) (≥5 drugs used long term). Intervention...

10.1136/bmj.n1585 article EN cc-by-nc BMJ 2021-07-13

The Prospective Oral Mucositis Audit assessed the incidence, duration, and determinants of severe oral mucositis (OM; WHO toxicity scale grades 3 to 4) in patients with multiple myeloma (MM) or non-Hodgkin's lymphoma (NHL) receiving high-dose conditioning chemotherapy before autologous stem-cell transplantation.Patients MM (n = 109; mean age, 57 +/- 8 years) NHL 88; 50 13 were treated melphalan (200 mg/m(2)) carmustine 300 mg/m(2), etoposide 800 cytarabine 1,600 140 mg/m(2) chemotherapy,...

10.1200/jco.2007.13.6028 article EN Journal of Clinical Oncology 2008-02-12

Abstract Background The objectives of the survey were to identify level influenza vaccination coverage in five European countries between 2001 and 2007, understand drivers barriers vaccination, assess intentions for winter 2007/08 as well major encouraging factors vaccination. Methods Between representative household surveys performed with telephone or mailed (France) interviews individuals aged 14 above. questionnaire used UK, Germany, Italy, France Spain was essentially same all seasons....

10.1186/1471-2458-8-272 article EN cc-by BMC Public Health 2008-08-01

Patient ratings of satisfaction with their postoperative pain treatment tend to be high even in those substantial pain. Determinants are poorly understood and have not previously been studied large-scale, international datasets. PAIN OUT, a European Union-funded acute registry research project, collects patient-reported outcome data on day 1 using the self-reported International Pain Outcome Questionnaire (IPO), patient, clinical, characteristics. We investigated correlates consistency...

10.1016/j.pain.2014.04.021 article EN Pain 2014-04-28

Abstract Aims We aimed to investigate the association of clinically overt and silent brain lesions with cognitive function in atrial fibrillation (AF) patients. Methods results enrolled 1227 AF patients a prospective, multicentre cohort study (Swiss-AF). Patients underwent standardized magnetic resonance imaging (MRI) at baseline after 2 years. quantified new small non-cortical infarcts (SNCIs) large or cortical (LNCCIs), white matter (WML), microbleeds (Mb). Clinically, were defined as...

10.1093/eurheartj/ehac020 article EN cc-by-nc European Heart Journal 2022-01-12

To study the effects of a primary care medication review intervention centred around an electronic clinical decision support system (eCDSS) on appropriateness and number prescribing omissions in older adults with multimorbidity polypharmacy compared discussion about line usual care.Cluster randomised trial.Swiss care, between December 2018 February 2021.Eligible patients were ≥65 years age three or more chronic conditions five long term medications.The to optimise pharmacotherapy eCDSS was...

10.1136/bmj-2022-074054 article EN cc-by BMJ 2023-05-24

Neutropenia is a life-threatening, dose-limiting toxicity of many chemotherapy regimens. The goals this study were to assess the incidence and risk chemotherapy-induced neutropenia, febrile neutropenia (FN) dose limitations in breast cancer lymphoma patients undergoing Europe. Four hundred forty-four 305 at 66 practices five European countries participated prospective, observational study. Predictors impaired delivery investigated using logistic regression model. In cancer, FN was low (6%);...

10.1007/s00520-008-0430-4 article EN cc-by-nc Supportive Care in Cancer 2008-03-19

Chemotherapy dose delay and/or reduction lower relative total intensity (RTDI) and may affect short- long-term outcome of metastatic breast cancer (MBC) patients. Based on 933 individual patients' data from 3 randomized MBC trials using an anthracycline taxane we examined the impact RTDI efficacy determined lowest optimal for Median time to disease progression (TTDP) overall survival (OS) all patients were 39 98 weeks. Overall higher was correlated with a shorter TTDP (log-rank p = 0.0525...

10.1186/1471-2407-11-131 article EN cc-by BMC Cancer 2011-04-12

Myelosuppression, particularly febrile neutropenia (FN), are serious dose-limiting toxicities that occur frequently during the first cycle of chemotherapy. Identifying patients most at risk developing FN might help physicians to target prophylactic treatment with colony-stimulating factor (CSF), in order decrease incidence, or duration, myelosuppression and facilitate delivery chemotherapy as planned. We present a model for occurrence chemotherapy, based on subgroup 240 non-Hodgkin lymphoma...

10.1111/j.1365-2141.2008.07514.x article EN other-oa British Journal of Haematology 2008-12-03

To investigate the planning of subgroup analyses in protocols randomised controlled trials and agreement with corresponding full journal publications.Cohort trial subsequent publications.Six research ethics committees Switzerland, Germany, Canada.894 involving patients approved by participating between 2000 2003 515 publications.Of 894 trials, 252 (28.2%) included one or more planned analyses. Of those, 17 (6.7%) provided a clear hypothesis for at least analysis, 10 (4.0%) anticipated...

10.1136/bmj.g4539 article EN cc-by-nc BMJ 2014-07-16

Several studies found that patients with atrial fibrillation (AF) have an increased risk of cognitive decline and dementia over time. However, the magnitude problem, associated factors underlying mechanisms remain unclear.This article describes design methodology Swiss Atrial Fibrillation (Swiss-AF) Cohort Study, a prospective multicentre national cohort study 2400 across 13 sites in Switzerland. Eligible must documented AF. Main exclusion criteria are inability to provide informed consent...

10.4414/smw.2017.14467 article EN cc-by Schweizerische medizinische Wochenschrift 2017-07-10

Background The incidence and predictors of atrial fibrillation ( AF ) progression are currently not well defined, clinical partly overlaps with rhythm control interventions RCI s). Methods Results We assessed type intercurrent s during yearly follow‐ups in 2869 prospectively followed patients paroxysmal or persistent . Clinical was defined as from to nonparoxysmal permanent An pulmonary vein isolation, electrical cardioversion, new treatment amiodarone. During a median follow‐up 3 years, the...

10.1161/jaha.119.012554 article EN cc-by-nc-nd Journal of the American Heart Association 2019-10-08

Background We previously found that 25% of 1,017 randomized clinical trials (RCTs) approved between 2000 and 2003 were discontinued prematurely, 44% remained unpublished at a median 12 years follow-up. aimed to assess decade later (1) whether rates completion publication have increased; (2) the extent which nonpublished RCTs can be identified in trial registries; (3) association reporting quality protocols premature discontinuation or nonpublication RCTs. Methods findings included 326 RCT...

10.1371/journal.pmed.1003980 article EN cc-by PLoS Medicine 2022-04-27
Coming Soon ...